Pancreatitis is one of the most common causes of acute gastrointestinal emergency in dogs. It ranges from mild, self-limiting inflammation to a severe, life-threatening disease with systemic complications including multi-organ failure. Most cases are idiopathic — no single cause is identified — but dietary indiscretion (especially high-fat meals), obesity, and certain medications are known triggers.

This article covers how veterinarians diagnose pancreatitis, what the SPEC cPLI test actually measures, what treatment looks like in hospital and at home, the role of the newly FDA conditionally approved drug Panoquell-CA1 (fuzapladib sodium), and what long-term management requires.

Quick answer

Pancreatitis is an inflammatory disease of the pancreas. In dogs, it is diagnosed by combining clinical signs (vomiting, abdominal pain, anorexia, diarrhea, lethargy) with a positive pancreatic lipase test (SPEC cPLI or SNAP cPL) and imaging findings (abdominal ultrasound). Treatment centers on supportive care: intravenous fluids, pain control, anti-nausea medication, and early nutritional support. Most mild cases have a good prognosis. Severe cases — particularly those with systemic complications — carry a guarded prognosis.

Panoquell-CA1 (fuzapladib sodium for injection) is the first drug to receive FDA conditional approval (November 2024) specifically for managing the clinical signs of acute onset pancreatitis in dogs. It is not a replacement for supportive care — it is administered alongside it.

What is pancreatitis

The pancreas has two functional compartments:

• Exocrine pancreas: produces digestive enzymes (amylase, lipase, trypsin, chymotrypsin, and others) that are released into the duodenum to break down food.
• Endocrine pancreas: produces insulin and glucagon, hormones that regulate blood sugar.

Pancreatitis occurs when digestive enzymes are activated prematurely — inside the pancreas instead of in the intestinal lumen. When trypsin activates within the pancreatic tissue, it triggers autodigestion: the pancreas essentially begins digesting itself, releasing inflammatory mediators that cause local tissue damage, swelling, and in severe cases, hemorrhage and necrosis.

Acute vs chronic pancreatitis

• Acute pancreatitis appears suddenly. It may be mild (interstitial/edematous) or severe (hemorrhagic/necrotizing). It is potentially reversible if the dog survives the acute episode.
• Chronic pancreatitis involves persistent or recurrent low-grade inflammation that causes irreversible fibrosis and atrophy of pancreatic tissue over time. Some dogs progress from acute to chronic disease.

Dogs that recover from acute pancreatitis can go on to develop chronic or recurrent disease, which is one reason long-term dietary and lifestyle management matters.

Clinical signs

The classic signs of acute pancreatitis in dogs include:

• Vomiting (often persistent and not responsive to initial anti-nausea medication)
• Anorexia (complete loss of appetite)
• Abdominal pain — dogs may assume a "praying position" (front end down, rear end up) to relieve pressure on the abdomen
• Diarrhea (may be bloody)
• Lethargy
• Dehydration
• Fever (in some cases)
• Abdominal distension

Not all dogs show all signs. Some dogs — particularly with chronic pancreatitis — show only vague signs like intermittent anorexia, mild lethargy, or occasional vomiting.

Emergency warning signs

Seek immediate veterinary care if your dog shows:

• Persistent vomiting and inability to keep water down
• Severe abdominal pain (restlessness, panting, reluctance to move, crying when picked up)
• Collapse or extreme lethargy
• Rapid breathing or difficulty breathing
• Pale or yellow gums

Diagnosis

No single test definitively diagnoses pancreatitis in dogs. The diagnosis is made by integrating clinical findings, laboratory results, and imaging.

Pancreatic lipase testing (SPEC cPLI and SNAP cPL)

The most useful blood tests for canine pancreatitis measure pancreatic lipase immunoreactivity — specifically, canine pancreatic lipase immunoreactivity (cPLI).

• SPEC cPLI (or Spec cPL) is a quantitative test run by a reference laboratory. It measures the exact concentration of pancreatic lipase in the blood.
  • Normal: < 200 µg/L
  • Grey zone: 200–399 µg/L (equivocal; repeat testing or additional diagnostics needed)
  • Consistent with pancreatitis: ≥ 400 µg/L
• SNAP cPL is an in-clinic semi-quantitative test that gives a positive or negative result. A positive SNAP cPL should be confirmed with a SPEC cPLI for monitoring and trending.

Pancreatic lipase testing is more sensitive and specific for canine pancreatitis than traditional serum amylase and lipase measurements, which are no longer recommended as primary diagnostic tools for pancreatitis in dogs.

Important limitation

A positive cPLI result supports the diagnosis but does not, by itself, confirm pancreatitis. The test can be elevated in dogs with other abdominal diseases (gastrointestinal foreign bodies, inflammatory bowel disease, hepatobiliary disease) and in dogs that have recently eaten a high-fat meal. Conversely, some dogs with chronic pancreatitis may have normal cPLI values because the pancreas has lost enough functional tissue that it can no longer mount a significant enzyme response.

Other bloodwork

• Complete blood count (CBC): may show elevated white blood cells (leukocytosis), anemia, or hemoconcentration due to dehydration.
• Chemistry panel: may show elevated liver enzymes (ALT, ALP), bilirubin, glucose, or BUN/creatinine. Hypocalcemia and hypoalbuminemia may be present in severe cases.
• Electrolytes: hypokalemia, hyponatremia, and hypochloremia are common due to vomiting and fluid losses.
• C-reactive protein (CRP): may be elevated as a marker of systemic inflammation.

Imaging

• Abdominal ultrasound is the most useful imaging modality for diagnosing pancreatitis in dogs. It can visualize pancreatic enlargement, peripancreatic fat saponification, abdominal effusion, and complications like pancreatic abscess or pseudocyst. However, ultrasound findings may be normal in up to 30–40% of dogs with pancreatitis, particularly in mild or early cases. The quality of the study depends heavily on the ultrasonographer's skill and the dog's body condition (gas in the GI tract can obscure the pancreas).
• Abdominal radiographs (X-rays) are less sensitive but may show loss of abdominal detail in the right cranial quadrant, displacement of the descending duodenum, or other supportive findings. Their primary role is ruling out other causes of acute abdomen (foreign body, intestinal obstruction).
• Pancreatic biopsy is the gold standard for definitive diagnosis but is rarely performed because dogs with acute pancreatitis are often poor anesthetic candidates, and the disease is usually treated based on clinical and laboratory criteria.

Treatment

Hospital care for acute pancreatitis

Treatment for moderate-to-severe acute pancreatitis requires hospitalization and includes:

1. Intravenous fluid therapy

The goals are to correct dehydration, maintain pancreatic perfusion, and correct electrolyte and acid-base abnormalities. Lactated Ringer's solution is often preferred over normal saline — recent evidence in both human and veterinary medicine suggests it may reduce disease progression.

2. Pain management

Pancreatitis is painful. All dogs with pancreatitis should receive analgesia. Options include:

• Opioids (buprenorphine, hydromorphone, methadone, or fentanyl constant-rate infusion for severe pain)
• Gabapentin or amantadine as adjuncts
• Ketamine or lidocaine constant-rate infusion for refractory pain

The specific protocol depends on the severity of pain, the dog's overall condition, and whether the dog is eating.

3. Anti-nausea (antiemetic) therapy

• Maropitant (Cerenia) — injectable or oral; the most commonly used first-line antiemetic in veterinary medicine.
• Ondansetron — useful as a second-line or combination antiemetic.
• Metoclopramide — may be used, but should be avoided if GI obstruction has not been ruled out.

4. Nutritional support

Previous recommendations to withhold food ("NPO" or "nothing by mouth") for several days during acute pancreatitis are outdated. Current evidence — from both human and veterinary medicine — supports early enteral nutrition once vomiting is controlled. Feeding the gut:

• Maintains intestinal mucosal integrity
• Reduces bacterial translocation
• Shortens hospital stays

If the dog will not eat voluntarily, options include placing a feeding tube (nasoesophageal or nasogastric) or using appetite stimulants (mirtazapine, capromorelin). The diet should be low-fat, highly digestible, and fed in small, frequent meals.

5. Panoquell-CA1 (fuzapladib sodium for injection)

Panoquell-CA1 is the first drug to receive FDA conditional approval specifically for the management of clinical signs associated with acute onset pancreatitis in dogs. It is administered as an intravenous injection while the dog is hospitalized.

How it works: Fuzapladib sodium is a selective inhibitor of leukocyte function–associated antigen-1 (LFA-1). By inhibiting LFA-1 activation, it blocks neutrophil adhesion and migration into the pancreas — the process that drives pancreatic lesion expansion and systemic inflammation. This is a targeted anti-inflammatory approach rather than a supportive care measure.

Conditional approval: The FDA granted conditional approval in November 2024 under application number 141-567. Conditional approval means the drug has been shown to be safe and to have a "reasonable expectation of effectiveness" when used according to the label. The sponsor (Ishihara Sangyo Kaisha, Ltd., marketed in the US by Ceva Animal Health) must continue collecting data toward full approval. Fuzapladib has been approved in Japan since 2018 under the brand names BRENDA-Z and BRENDA.

Pilot field study: In the study supporting conditional approval, 61 client-owned dogs were enrolled and 36 were included in the effectiveness analysis. Dogs treated with fuzapladib sodium showed a statistically significant reduction in MCAI-7 (Multivariate Canine Acute Pancreatitis Index) clinical scores compared to dogs receiving symptomatic care alone (p = 0.0193).

Safety considerations:

• Safe use has not been evaluated in dogs with cardiac disease, hepatic failure, or renal impairment.
• Not evaluated in pregnant, lactating, or breeding dogs, or puppies under 6 months.
• Should not be used in dogs with known hypersensitivity to fuzapladib sodium.
• It is a highly protein-bound drug; concurrent use with other highly protein-bound medications has not been studied.
• The most common side effects in the pilot field study were anorexia, digestive tract disorders, respiratory tract disorders, and jaundice.
• Not for use in humans. Anyone who is pregnant, breastfeeding, or planning to become pregnant should avoid handling the drug.

6. Other treatments

• Antibiotics are not a standard component of treatment. Pancreatitis is a sterile inflammatory process in most cases, and bacterial infection is rare. Antibiotics may be considered if there is evidence of bacterial translocation, sepsis, or pancreatic abscess.
• Plasma transfusion may be considered in severe cases to replace depleted protease inhibitors (alpha-macroglobulin) and provide albumin.
• Surgical intervention is rarely needed but may be required for complications like pancreatic abscess, pseudocyst, or biliary obstruction.

Predisposing factors and causes

In most cases, no single cause is identified (idiopathic). Known predisposing factors include:

• Dietary indiscretion — especially ingestion of a single high-fat meal (table scraps, garbage, fatty meat)
• Obesity — overweight dogs are at higher risk
• Hyperlipidemia — elevated blood triglycerides (particularly in Miniature Schnauzers)
• Certain medications — corticosteroids (controversial but reported), potassium bromide, azathioprine, L-asparaginase, sulfa drugs
• Concurrent diseases — inflammatory bowel disease (IBD), diabetes mellitus, hypothyroidism, biliary disease, Cushing's disease (hyperadrenocorticism), hypercalcemia
• Breed predisposition — Miniature Schnauzers, Yorkshire Terriers, Cocker Spaniels, Dachshunds, Poodles, and some terrier breeds are overrepresented in studies
• Trauma — blunt abdominal trauma or surgical manipulation of the pancreas

Prognosis

• Mild (interstitial) pancreatitis: Good prognosis with prompt supportive care. Most dogs recover within a few days.
• Severe (hemorrhagic/necrotizing) pancreatitis: Guarded prognosis. Systemic complications — including hypothermia, acidosis, hypocalcemia, disseminated intravascular coagulation (DIC), and multi-organ failure — are risk factors for a poor outcome.
• Chronic pancreatitis: Variable. Many dogs can be managed long-term with diet and monitoring, but flare-ups are common and progressive pancreatic damage may eventually lead to exocrine pancreatic insufficiency (EPI) or diabetes mellitus.

Long-term management and prevention

For dogs that have recovered from acute pancreatitis — or dogs diagnosed with chronic pancreatitis — long-term management focuses on preventing recurrence:

Diet

• Feed a low-fat, highly digestible diet consistently. This is the single most important preventive measure.
• Avoid table scraps, fatty treats, rawhides, pig ears, and any high-fat foods — even a single high-fat meal can trigger a flare.
• Commercially available gastrointestinal or low-fat prescription diets are commonly recommended (e.g., Royal Canin Gastrointestinal Low Fat, Hill's i/d Low Fat, Purina EN Gastroenteric Low Fat).
• Feed measured meals at regular intervals rather than free-feeding.
• Maintain strict consistency — "just one piece of bacon" is enough to cause a recurrence in susceptible dogs.

Weight management

• If the dog is overweight, work with your veterinarian on a structured weight-loss plan. Obesity is a clear risk factor.

Avoid high-risk medications

• Discuss any new medications with your veterinarian. Certain drugs (including some NSAIDs, corticosteroids, and anticonvulsants) may increase pancreatitis risk in susceptible dogs.

Monitoring

• Dogs with chronic pancreatitis may benefit from periodic SPEC cPLI monitoring, serial abdominal ultrasounds, and screening for concurrent conditions (IBD, diabetes, EPI).
• Watch for early signs of flare: decreased appetite, subtle vomiting, lip-smacking, or reluctance to eat.

When to seek emergency care

If your dog has a history of pancreatitis and shows any of the following, do not wait:

• Vomiting that persists for more than 12 hours
• Complete refusal to eat for more than 24 hours
• Abdominal pain (hunched posture, restlessness, crying when touched)
• Diarrhea with blood
• Lethargy or collapse

What to discuss with your veterinarian

• What did the SPEC cPLI or ultrasound show? Ask for the actual numeric value and how it compares to normal. If ultrasound was performed, ask what was seen.
• Is this acute or chronic? The distinction matters for long-term prognosis and management.
• What diet should my dog eat? Get a specific recommendation — not just "low fat" but a specific product and feeding amount.
• What is the follow-up plan? When should bloodwork or cPLI be rechecked? When should an ultrasound be repeated?
• Should we screen for concurrent diseases? Pancreatitis often coexists with IBD, diabetes, or hyperadrenocorticism. If your dog has recurrent episodes, discuss a broader workup.
• Is my dog a candidate for Panoquell-CA1? If your dog is hospitalized with acute pancreatitis, ask whether this drug is appropriate and available at your clinic.
• What signs should prompt an emergency visit? Get specific guidance on what to watch for at home.

Key points

• Pancreatitis is a painful inflammatory disease of the pancreas that ranges from mild to life-threatening.
• Diagnosis requires integrating clinical signs, SPEC cPLI results, and imaging — no single test is definitive.
• Treatment is primarily supportive: IV fluids, pain control, anti-nausea medication, and early nutrition.
• Panoquell-CA1 (fuzapladib sodium) is the first FDA conditionally approved drug for acute canine pancreatitis. It targets the neutrophil inflammatory cascade through LFA-1 inhibition and is administered IV during hospitalization.
• Long-term prevention centers on a strict low-fat diet and weight management.
• Dogs that have had one episode of acute pancreatitis are at risk for recurrence and progression to chronic disease.

Sources

• FDA — Conditional Approval of Panoquell-CA1 (fuzapladib sodium for injection). https://content.govdelivery.com/accounts/USFDA/bulletins/3380c44
• FDA — Freedom of Information Summary: Conditional Approval Application 141-567. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13134
• AVMA — FDA conditionally approves first drug for acute onset of pancreatitis in dogs. https://www.avma.org/news/fda-conditionally-approves-first-drug-acute-onset-pancreatitis-dogs
• Merck Veterinary Manual — Pancreatitis in Dogs and Cats. https://www.merckvetmanual.com/digestive-system/the-exocrine-pancreas/pancreatitis-in-dogs-and-cats
• VCA Animal Hospitals — Pancreatitis in Dogs. https://vcahospitals.com/know-your-pet/pancreatitis-in-dogs
• dvm360 — Management of pancreatitis in dogs and the role of Panoquell-CA1. https://www.dvm360.com/view/management-of-pancreatitis-in-dogs-and-the-role-of-panoquell-ca1-fuzapladib-sodium-for-injection-
• Panoquell-CA1 — Product website (Ceva Animal Health). https://www.panoquell.com
• Mansfield CS, Jones BR (2023) — Management of acute pancreatitis in dogs: a critical appraisal with focus on feeding and analgesia. Journal of Small Animal Practice. https://pubmed.ncbi.nlm.nih.gov/25586804